TRIUMPH Maintenance Study: Keeping Weight Off After Retatrutide

The TRIUMPH maintenance study addresses the elephant in the room of pharmaceutical weight loss: what happens when treatment stops? Retatrutide's Phase 2 trial showed extraordinary weight loss of 24.2% in 48 weeks (Jastreboff et al., NEJM 2023), but experience with other GLP-1 medications tells us that weight regain after discontinuation is common. This maintenance trial will determine whether retatrutide can break that pattern — through continued treatment, reduced dosing, or perhaps through sustained metabolic changes that persist after stopping.

The Weight Regain Problem

Weight regain after stopping obesity medications is not a failure of willpower — it is biology. The body defends its weight through multiple mechanisms:

• Metabolic adaptation: After weight loss, metabolic rate decreases, meaning you burn fewer calories at rest than someone who was always at your new weight
• Hormonal changes: Hunger hormones (ghrelin) increase while satiety hormones (leptin) decrease after weight loss
• Neural adaptation: Brain reward pathways become more responsive to food cues after weight loss
• Set point theory: The body appears to have a defended weight range that it actively tries to return to

Data from semaglutide's STEP 1 extension trial showed that participants regained approximately two-thirds of their lost weight within one year of stopping treatment. Tirzepatide data shows similar patterns. These findings have led to the consensus that obesity, like hypertension or diabetes, requires long-term pharmacological treatment.

Maintenance Study Design

The TRIUMPH maintenance study likely tests several scenarios:

The Glucagon Maintenance Hypothesis

One intriguing possibility is that retatrutide's glucagon component may produce more durable metabolic changes than single or dual agonists:

• Increased metabolic rate: Glucagon-driven thermogenesis may partially counteract metabolic adaptation, maintaining a higher metabolic rate even after dose reduction
• Liver fat clearance: The dramatic liver fat reduction (up to 86%) may produce lasting metabolic improvements even after treatment ends
• Body composition: If retatrutide preserves more lean mass (through preferential fat burning), the resulting body composition may support better weight maintenance

These are hypotheses. The maintenance study will provide actual data.

Practical Implications

Maintenance study results will answer critical practical questions:

• Duration of treatment: Will patients need to take retatrutide indefinitely, or can they taper off after reaching their goal?
• Cost sustainability: If a reduced maintenance dose works, long-term costs become more manageable
• Side effect management: Lower maintenance doses would mean reduced side effects during the lifelong treatment phase
• Insurance coverage: Data on long-term necessity supports the case for ongoing insurance coverage

Start Treatment Today

Current GLP-1 medications are designed for long-term use and are available now:

• Compounded semaglutide: $99/month
• Compounded tirzepatide: $125/month

Learn more about how to get started with long-term weight management.